n'gn'g

At the recently concluded AMWC 2025 (Aesthetic & Anti-Aging Medicine World Congress) in Chengdu, Novi Orea—a medical aesthetics brand under Yaohai Novagen specializing in recombinant humanized Type III collagen—officially launched its new product: Novi Orea Qiyan Recombinant Collagen Repair Gel. This new product, featuring exclusive patented technology, has garnered widespread attention across the industry.

In the fields of regenerative medicine and dermatology, the core of recombinant humanized collagen technology relies heavily on the rational design of its amino acid sequence and the biological activity of its spatial structure. The recombinant humanized Type III collagen used by Novi Orea is built upon a specifically designed amino acid sequence and is protected by an exclusive invention patent (Patent No.: ZL202310797546.3), ensuring the product's scientific validity and advanced nature right from the design stage.

(Exclusive Invention Patent)

Scientific Design "Decodes" the Source Code of Youth: Non-repetitive Assembly of Active Type III Collagen Sequence Structures

Traditional recombinant collagen technologies often face challenges such as sequence repetition and structural instability, resulting in biological activity that falls far short of the body's own collagen. Based on the relationship between structure and function, Novi Orea’s recombinant humanized Type III collagen involves the systematic screening and optimization of functional segments, thereby creating a brand-new amino acid sequence with superior performance.

Functional Domain Screening: Through biological analysis, three key core functional segments (amino acid positions: 316–471; 646–777; 841–1026) were selected from the full-length sequence of human Type III collagen (excluding telopeptides). These segments were chosen for their high activity, high hydrophilicity, and potential triple-helix activity. The precise screening of these functional segments is crucial for determining the final functionality and structural stability of the recombinant Type III collagen.

Sequence Optimization and Construction: The core functional fragments identified during screening underwent de-redundancy processing and optimized assembly. This resulted in the construction of a novel, continuous, and stable sequence comprising 410 amino acids. Derived entirely from human-origin sequences without repetitive fragment splicing, the design ensures the preservation of the activity of each selected fragment.

Technical Characteristics and Biological Advantages of the Patented Sequence

The design of the patented sequence endows the Novi Orea product with several key technical characteristics:

1. Human Origin and Non-repetitive Nature

The constructed 410-amino-acid sequence is derived entirely from the natural sequence of human type III collagen, ensuring excellent biocompatibility. Furthermore, the design avoids meaningless repetition of functional domains, resulting in a compact, non-redundant, single polypeptide chain.

2. Potential to Form a Triple-Helix Structure

The screening and assembly strategy for the patented sequence was guided by the goal of creating a stable triple-helix structure in the final product. The triple-helix structure of type III collagen serves as the physical basis for its specific binding to cell-surface receptors (such as integrins), thereby facilitating biological functions like cell adhesion, migration, and proliferation. Consequently, the sequence design provides a structural foundation for the product's high biological activity.

3. Well-defined Biological Functional Mechanism

Based on the aforementioned structure, the mechanism of action for Novi Orea recombinant type III collagen extends beyond mere physical filling. Crucially, by mimicking the function of endogenous human type III collagen, it interacts specifically with surrounding cells and tissues to regulate cell behavior, promote the synthesis of autologous extracellular matrix, and facilitate tissue regeneration.

The patented sequence design of Novi Orea recombinant type III humanized collagen demonstrates the strong competitive advantage held by Yaohai Novagen in the field of recombinant humanized collagen—an advantage underpinned by the robust R&D capabilities of its parent company, Yaohai Biology. This design also establishes a new technical paradigm and development trajectory for the industrial application of recombinant collagen.

About Yaohai Novagen

Yaohai Novagen, a wholly-owned subsidiary of Yaohai Bio, is a platform-level medical device enterprise integrating R&D, production, and sales. Centered on synthetic biology technology, the company focuses on the field of innovative medical aesthetic raw materials and products. Leveraging over 13 years of experience in the R&D, production, and regulatory approval of biological agents, it aims to become a trusted global innovation partner in the medical aesthetics and health industry.

Novi Orea

Novi Orea is a medical aesthetic brand under Yaohai Novagen Bio, dedicated to the R&D, production, and sales of recombinant humanized type III collagen products. Grounded in dermatological science and biology, the brand is committed to exploring endogenous skin anti-aging solutions. Derived from the Latin roots *Novus* (new), *Vita* (life), and *Orea* (beauty), the brand embodies a unique value proposition: "Sculpting beauty from within, promising a renewed radiance every day."

Jiangsu Yaohai Novagen Bio-technology Co., Ltd.

Jiangsu Yaohai Novagen Bio-technology Co., Ltd.

Address: Building G29, No. 801 Jiankang Avenue, Taizhou City, Jiangsu Province

Add: Building G29, No. 801 Jiankang Avenue, Taizhou City, Jiangsu Province, China.

Website: https://www.yhnx.com.cn

Contact Us

Jiangsu Yaohai Novagen Bio-technology Co., Ltd.

Contact Person: Liu Yu (15380896633)

Address: Building G29, No. 801 Jiankang Avenue, Taizhou City, Jiangsu Province